Cytokine therapy in immune-mediated demyelinating diseases of the central nervous system: A novel gene therapy approach

Journal of Neuroimmunology

Volumn 107, Issue 2, 2000, Pages 184-190

  Martino, Gianvito ^a   Poliani, Pietro L ^a   Furlan, Roberto ^a   Marconi, Peggy ^b   Glorioso, Joseph C ^c   Adorini, Luciano ^d   Comi, Giancarlo ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b SAN RAFFAELE SCIENTIFIC INSTITUTE   (Italy)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d ROCHE MILANO RICERCHE   (Italy)

Author keywords

Cytokines; Experimental autoimmune encephalomyelitis; Gene therapy; Herpes simplex type 1 derived viral vectors; Inflammation; Multiple sclerosis

Indexed keywords

CYTOKINE; INTERLEUKIN 4; MONOCYTE CHEMOTACTIC PROTEIN 1; VIRUS VECTOR;

ALLERGIC ENCEPHALOMYELITIS; CENTRAL NERVOUS SYSTEM DISEASE; CONFERENCE PAPER; CYTOKINE RELEASE; DEMYELINATION; GENE THERAPY; GENETIC ENGINEERING; HERPES SIMPLEX VIRUS 1; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; TREATMENT OUTCOME;

ANIMALS; CHEMOKINE CCL2; DISEASE MODELS, ANIMAL; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; GENE THERAPY; GENETIC VECTORS; HERPESVIRUS 1, HUMAN; INJECTIONS, SPINAL; INTERFERON TYPE II; INTERLEUKIN-4; LAC OPERON; MICE; MICE, INBRED BALB C; MULTIPLE SCLEROSIS;

EID: 0034710341     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-5728(00)00236-8     Document Type: Conference Paper

References (37)

1. Bachmann R., Eugster H.P., Frei K., Fontana A., Lassmann H. Impairment of TNF-receptor-1 signaling but not fas signaling diminishes T-cell apoptosis in myelin oligodendrocyte glycoprotein peptide-induced chronic demyelinating autoimmune encephalomyelitis in mice. Am. J. Pathol. 154:1999;1417-1422.
2. Barkhof F., van Waesberghe J.H., Uitdehaag B.M., Polman C.H. Ibuprofen does not suppress active multiple sclerosis lesions on gadolinium-enhanced MR images. Ann. Neurol. 42:1997;982.
3. Battistini L., Borsellino G., Sawicki G., Poccia F., Salvetti M., Ristori G., Brosnan C.F. Phenotypic and cytokine analysis of human peripheral blood gamma delta T cells expressing NK cell receptors. J. Immunol. 159:1997;3723-3730.
4. Beck J., Rondot P., Catinot L., Falcoff E., Kirchner H., Wietzerbin J. Increased production of interferon gamma and tumor necrosis factor precedes clinical manifestation in multiple sclerosis: do cytokines trigger off exacerbations? Acta Neurol. Scand. 78:1988;318-323.
5. Brosnan C.F., Cannella B., Battistini L., Raine C.S. Cytokine localization in multiple sclerosis lesions: correlation with adhesion molecule expression and reactive nitrogen species. Neurology. 45:(Suppl. 6):1995;S16-21.
6. Calabresi P.A., Tranquill L.R., McFarland H.F., Cowan E.P. Cytokine gene expression in cells derived from CSF of multiple sclerosis patients. J. Neuroimmunol. 89:1998;198-205.
7. Calabresi P.A., Fields N.S., Maloni H.W., Hanham A., Carlino J., Moore J., Levin M.C., Dhib-Jalbut S., Tranquill L.R., Austin H., McFarland H.F., Racke M.K. Phase 1 trial of transforming growth factor beta 2 in chronic progressive MS. Neurology. 51:1998;289-292.
8. DeLuca N.A., McCarthy A.M., Schaffer P.A. Isolation and characterization of deletion mutants of herpes simplex virus type 1 in the gene encoding immediate-early regulatory protein ICP4. J. Virol. 56:1985;558-570.
9. Ferber I.A., Brocke S., Taylor-Edwards C., Ridgway W., Dinisco C., Steinman L., Dalton D., Fathman C.G. Mice with a disrupted IFN-gamma gene are susceptible to the induction of experimental autoimmune encephalomyelitis (EAE). J. Immunol. 156:1996;5-7.
10. Furlan R., Poliani P.L., Galbiati F., Bergami A., Grimaldi L.M., Comi G., Adorini L., Martino G. Central nervous system delivery of interleukin 4 by a nonreplicative herpes simplex type 1 viral vector ameliorates autoimmune demyelination. Hum. Gene Ther. 9:1998;2605-2617.
11. Furlan, R., Martino, G., Galbiati, F., Poliani, P.L., Smiroldo, S., Bergami, A., Desian, G., Comi, G., Flavell, R., Su, M., Adorini, L., 1999. Caspase-1 regulates the inflammatory process leading to autoimmune demyelination. J. Immunol. (in press).
12. Glorioso J.C., DeLuca N.A., Fink D.J. Development and application of herpes simplex virus vectors for human gene therapy. Annu. Rev. Microbiol. 49:1985;675-710.
13. Kerschensteiner M., Gallmeier E., Behrens L., Leal V.V., Misgeld T., Klinkert W.E.F., Kolbeck R., Hoppe E., Oropeza-Wekerle R.L., Bartke I., Stadelmann C., Lassmann H., Wekerle H., Hohlfeld R. Activated human T cells, B cells, and monocytes produce brain-derived neurotrophic factor in vitro and in inflammatory brain lesions: a neuroprotective role of inflammation? J. Exp. Med. 189:1999;865-870.
14. Khan O.A., Xia Q., Bever C.T. Jr., Johnson K.P., Panitch H.S., Dhib-Jalbut S.S. Interferon beta-1b serum levels in multiple sclerosis patients following subcutaneous administration. Neurology. 46:1996;1639-1643.
15. Kieiser B.C., Storch M.K., Archelos J.J., Martino G., Hartung H.P. Effector pathways in immune mediated central nervous system demyelination. Curr. Opin. Neurol. 12:1999;323-336.
16. Krakowski M., Owens T. Interferon-gamma confers resistance to experimental allergic encephalomyelitis. Eur. J. Immunol. 26:1996;1641-1646.
17. Liu J., Marino M.W., Wong G., Grail D., Dunn A., Bettadapura J., Slavin A.J., Old L., Bernard C.C. TNF is a potent anti-inflammatory cytokine in autoimmune-mediated demyelination. Nat. Med. 4:1998;78-83.
18. Lucchinetti C.F., Bruck W., Rodriguez M., Lassmann H. Distinct patterns of multiple sclerosis pathology indicates heterogeneity on pathogenesis. Brain Pathol. 6:1996;259-274.
19. Marconi P., Krisky D., Oligino T., Poliani P.L., Ramakrishnan R., Goins W.F., Fink D.J., Glorioso J.C. Replication-defective herpes simplex virus vectors for gene transfer in vivo. Proc. Natl. Acad. Sci. USA. 93:1996;11319-11320.
20. Martino G., Hartung H.P. Immunopathogenesis of multiple sclerosis: the role of T cells. Curr. Opin. Neurol. 12:1999;309-321.
21. Martino G., Consiglio A., Franciotta D.M., Corti A., Filippi M., Vandenbroeck K., Sciacca F.L., Comi G., Grimaldi L.M.E. Tumor necrosis factor α and its receptors (R1 and R2) in relapsing-remitting multiple sclerosis. J. Neurol. Sci. 152:1997;51-61.
22. Martino G., Grohovaz F., Brambilla E., Codazzi F., Consiglio A., Clementi E., Filippi M., Comi G., Grimaldi L.M.E. Proinflammatory cytokines regulate antigen-independent T-cell activation by two separate calcium-signaling pathways in multiple sclerosis patients. Ann. Neurol. 43:1998;340-349.
23. Martino G., Furlan R., Galbiati F., Poliani P.L., Bergami A., Grimaldi L.M., Adorini L., Comi G. A gene therapy approach to treat demyelinating diseases using non-replicative herpetic vectors engineered to produce cytokines. Mult. Scler. 4:1998;222-227.
24. Meinl E., Hoch R.M., Dornmair K., de Waal Malefyt R., Bontrop R.E., Jonker M., Lassmann H., Hohlfeld R., Wekerle H., 't Hart B.A. Encephalitogenic potential of myelin basic protein-specific T cells isolated from normal rhesus macaques. Am. J. Pathol. 150:1997;445-453.
25. Miller A., Shapiro S., Gershtein R., Kinarty A., Rawashdeh H., Honigman S., Lahat N. Treatment of multiple sclerosis with copolymer-1 (Copaxone): implicating mechanisms of Th1 to Th2/Th3 immune-deviation. J. Neuroimmunol. 92:1998;113-121.
26. Olsson T. Cytokine-producing cells in experimental autoimmune encephalomyelitis and multiple sclerosis. Neurology. 45:(Suppl. 6):1995;S11-S15.
27. Panitch N.L., Hirsch R.L., Haley A.S., Johnson K.P. Exacerbations of multiple sclerosis in patients treated with gamma interferon. Lancet. 1:1987;893-895.
28. Rieckmann P., Albrecht M., Kitze B., Weber T., Tumani H., Broocks A., Luer W., Helwig A., Poser S. Tumor necrosis factor-alpha messenger RNA expression in patients with relapsing-remitting multiple sclerosis is associated with disease activity. Ann. Neurol. 37:1995;82-88.
29. Rudick R.A., Ransohoff R.M., Lee J.C., Peppler R., Yu M., Mathisen P.M., Tuohy V.K. In vivo effects of interferon beta-1a on immunosuppressive cytokines in multiple sclerosis. Neurology. 50:1998;1294-1300.
30. Selmaj K.W., Raine C.S., Cannella B., Brosnan C.F. Identification of lymphotoxin and tumor necrosis factor in multiple sclerosis lesions. J. Clin. Invest. 87:1991;949-954.
31. Smith D.R., Balashov K.E., Hafler D.A., Khoury S.J., Weiner H.L. Immune deviation following pulse cyclophosphamide/methylprednisolone treatment of multiple sclerosis: increased interleukin-4 production and associated eosinophilia. Ann. Neurol. 42:1997;313-318.
32. Steinman L. A few autoreactive cells in an autoimmune infiltrate control a vast population of non specific cells: a tale of smart bombs and the infantry. Proc. Natl. Acad. Sci. USA. 93:1996;2253-2256.
33. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group, 1996. Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: experience during the first three years. Neurology 47, 889-894.
34. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group, 1999. TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. Neurology 53, 457-465.
35. van Oosten B.W., Barkhof F., Truyen L., Boringa J.B., Bertelsmann F.W., von Blomberg B.M., Woody J.N., Hartung H.P., Polman C.H. Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology. 47:1996;1531-1534.
36. Willenborg D.O., Fordham S., Bernard C.C., Cowden W.B., Ramshaw I.A. IFN-gamma plays a critical down-regulatory role in the induction and effector phase of myelin oligodendrocyte glycoprotein-induced autoimmune encephalomyelitis. J. Immunol. 157:1996;3223-3227.
37. Yule S.M., Price L., Pearson A.D., Boddy A.V. Cyclophosphamide and ifosfamide metabolites in the cerebrospinal fluid of children. Clin. Cancer Res. 3:1997;1985-1992.